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Neuroendocrine tumours comprise a small percentage of pancreatic neoplasia (10%) (1). Diagnosis of neuroendocrine tumours
is diﬃcult, especially if the tumours are small and nonfunctional. CT scans, MRI, and nuclear scans are suﬃciently sensitive
assessment tools for tumours with diameters of at least 2cm; otherwise, the sensitivity and speciﬁcity of these techniques
is less than 50% (2). Myasthenia gravis (MG) is a heterogeneous neuromuscular junction disorder that is primarily caused
when antibodies form against the acetylcholine receptors (Ab-AchR). MG can develop in conjunction with neoplasia, making
MG a paraneoplastic disease. In those cases, MG is most commonly associated with thymomas and less frequently associated
with extrathymic malignancies. The mechanism underlying this paraneoplastic syndrome has been hypothesized to involve an
autoimmune response against the tumour cells (3). No published reports have linked malignant pancreatic diseases with MG.
Here, we report the case of a young woman, negative for Ab-AchR, with a neuroendocrine tumour in the pancreatic head, who
experienced a complete resolution of her MG-like syndrome after surgical enucleation of the tumour.
1.Introduction
Advances in radiological imaging for the evaluation of
patients suspected to have pancreatic tumours have led to
increaseddetectionofthistypeoftumour[1].However,neu-
roendocrine tumours of the pancreas are usually very small
and standard radiological techniques are not suﬃciently
sensitive [2]. If the neuroendocrine tumours are functional,
their presentation is usually quite typical and the presenting
symptoms can guide us to search for tumours in the small
bowel, gastric wall, or pancreatic gland. When the symptoms
are unusual or the tumour is nonfunctional, the diagnosis is
much more challenging.
2.CaseReport
A 32-year-old woman with a previous history of thy-
roidectomy for a multinodular goitre, within the past year,
was under the supervision of a neurologist for weakness,
symmetric eyelid ptosis, and a progressive loss of strength
consistent with myasthenia gravis (MG). CT scan of the
neck revealed a fatty inﬁltration of the thymus gland. The
patienthadapositiveTensilontest.Thecardiac,thoracic,and
abdominal examinations were unremarkable.
The patient started a therapy of 60mg pyridostigmine,
four times daily (Mestinon), achieving a partial clinical
response but worsening of the symptoms (eyelid ptosis) after
3 months. IgG therapy (25g/day for 5 days) was initiated,
and a partial clinical response was achieved. This unusual
course, in conjunction with a negative test for Ab-AchR, led
to additional investigations.
The patient underwent a PET scan that revealed a
“captatio” in the head of the pancreas. She was then referred
to our Endoscopy Unit for an endoscopic ultrasound (EUS).
EUS revealed a small hypoechoic lesion in the head of the
pancreas, 9.3mm × 8mm, with regular borders (Figure 1).2 Case Reports in Medicine
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Figure 1: Endoscopic ultrasound of the hypoechoic lesion in the
pancreatic head.
Figure 2: Hematoxylin-eosin staining of the specimen obtained
with ﬁne-needle aspiration. Magniﬁcation = 20x.
The lesion was located near the pancreatic duct. The
pancreatic body and tail were unremarkable. At the same
time, a ﬁne-needle aspiration biopsy (FNAB) of the lesion
was performed with a 22 G needle, with 2 passes. After
EUS, the patient underwent endoscopic retrograde cholan-
giopancreatography with sphincterotomy and pancreatic
ductcannulation.Weperformedapancreaticjuiceaspiration
and conducted tests for serum carcinoembryonic antigen
(CEA), chromogranin, and carbohydrate antigen (CA)
19.9.
Six hours after the procedure, the patient developed
acute abdominal pain, with elevations in serum amylase and
lipase. A CT scan revealed a dishomogeneous pancreatic
parenchyma, which suggested edematous pancreatitis with
abdominal, pleural, and pericardial eﬀusion. Conserva-
tive treatment was performed with fast ﬂuid resuscita-
tion, gastric aspiration probe, and IV administration of
piperacillin/tazobactam (4.5g, twice). Chromogranin, CEA,
Ca19.9, and neurone-speciﬁc enolase levels in the blood
sample and pancreatic juice were within normal limits. Tests
for 5-hydroxyindoleacetic acid and vanilmandelic acid in
the urine were negative. The cytopathologist conﬁrmed a
well-diﬀerentiated neuroendocrine tumour in the sample
obtained through FNAB (Figures 2, 3,a n d4). The patient
Figure 3: Chromogranin staining of the specimen obtained with
ﬁne-needle aspiration. Magniﬁcation = 20x.
Figure 4: Progesterone staining of the surgical specimen.
was discharged after 2 weeks, and the surgeons planned for
enucleation of the small lesion in the pancreatic head.
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puncture of the lesion and insertion of Visicoil (IBA) to
help localize the lesion during surgery. The patient under-
went surgery with intraoperative ultrasound and successful
localization of the lesion in the pancreatic head. The patient
was discharged after 2 weeks, with a small pancreatic ﬁstula
that healed spontaneously in 2 weeks. Neurologist decided
to discontinue Pyridostigmine 1 year after surgery, and the
patient has been symptom-free for 3 years after-surgery.
3. Discussion
MG is an immune-mediated neurological disease. The most
common symptoms at onset include eyelid ptosis, muscular
weakness, and fatigability. The prevalence of the disease
in the USA is reportedly 20 per 100,000 people in the
general population, but the true prevalence is probably
higher because MG frequently goes undiagnosed. Women
a r em o r eo f t e na ﬀected with MG in the second and third
d e c a d e so fl i f e ,w h e r e a sm e na r em o r eo f t e na ﬀected in
the sixth decade. MG is frequently associated with positive
tests for Ab-AChR but, in 15% of patients with generalizedCase Reports in Medicine 3
MG, Ab-AChR tests are negative [3]. Although removal
of the primary tumour may be complete, the neurological
symptoms usually do not disappear and recurrence of MG
symptoms is quite frequent. The mechanism underlying
this phenomenon involves an autoimmune response. MG is
sometimes considered a paraneoplastic syndrome associated
with cancers of the thymus and extrathymus [3]. An
underlying neoplastic disease must be suspected if tests
of Ab-AChR are negative and occur in conjunction with
atypical onset of symptoms.
Neuroendocrine tumours are considered as rare neopla-
sia arising from the gut. They are classiﬁed as functional
or nonfunctional according to the presence or absence,
respectively, of clinical symptoms associated with the pro-
duction and secretion of various neuroendocrine mediators
(serotonin, somatostatin, chromogranin, gastrin, insulin,
glucagon, histamine, glucose-dependent insulinotropic pep-
tide, neurotensin, vasoactive intestinal peptide, pancreatic
polypeptide). Only 10% of neuroendocrine tumours are
functional, and the symptoms described most frequently
for neuroendocrine syndromes include ﬂushing (80%),
diarrhea (75%), weight loss, nettle rash, itching, sweating,
hypercalcaemia, acromegaly, or Cushing syndrome, which
are due to the production of speciﬁc neuromediators.
Diagnosis of neuroendocrine tumours is diﬃcult, espe-
cially if the tumour is small and nonfunctional. Published
reports suggest that CT scans have a sensitivity range of 11–
66% and a speciﬁcity range of 83–100% whereas MRI has
a sensitivity range of 20–25% and a speciﬁcity range of 89–
100%. Nuclear scans have good sensitivity (58–100%) if the
tumour diameter is at least 2cm; otherwise, the sensitivity
is less than 50%. A speciﬁcity range has not been reported
for nuclear scans. EUS can be used to diagnose very small
tumours, and published reports of prospective and retro-
spective studies suggest that this technique has a sensitivity
range of 57–100%. EUS is extremely useful for identifying
pancreatic head tumours [4–6]. However, the sensitivity
decreases from 92% for tumours in the pancreatic head to
40% for tumours in the pancreatic tail [7]. During EUS,
it is possible to perform FNAB to obtain tissue specimens
for subsequent cytopathological and immunohistochemical
analyses [8]. The accuracy of EUS-FNAB for the diagnosis
of pancreatic carcinoma and neuroendocrine tumours is
reported to be 80%–95% [9–12] and 46%–83%, respectively
[13, 14].
There are no published reports regarding neurologi-
cal disorders associated with pancreatic neoplasms, only
reports regarding pancreatic cancer in association with a
paraneoplastic syndrome (deep vein thrombosis, coagu-
lation disorders, hypercalcaemia, acromegaly, or Cushing
syndrome). This report is the ﬁrst description of a small
neuroendocrine tumour of the pancreas, diagnosed via EUS,
that was associated with paraneoplastic MG. However, two
points must be considered regarding the clinical relevance
of this case report. First, this is a rare form of pancreatic
tumour, presenting with a better prognostic score than
pancreatic adenocarcinoma. The better prognosis was due
to the relatively small diameter of the tumour at the
time of diagnosis, and to a well-diﬀerentiated type of
this tumour with low mythotic index. Many reports of
symptoms attributed to the secretion of neuromediators
have been based on histopathological examination of the
neuroendocrine tumour, but a neurological syndrome has
never been reported. A retrospective analysis of the data
from patients that underwent surgical resection of neu-
roendocrine neoplasia, registered as “asymptomatic,” may
reveal neurological symptoms missed during the previous
analysis. Second, a complete response to surgical therapy is
quite uncommon with neurological disorders. Paraneoplas-
tic neurological syndrome is quite common in patients with
breast cancer, but these patients rarely recover after surgical
ablation of the primary tumour, even after many years of
disease-free survival. In the present case, pharmacological
therapy was discontinued after 1 year, and the patient is still
symptom-free after 3 years. The diﬀerences in outcome are
probably due to diﬀerences in the underlying pathogenetic
pathways; more studies are needed to fully understand these
syndromes.
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